Acknowledgments

The HAT studies were performed jointly by the combined clinical research team of Behring-Werke AG, Hoechst, and Aventis. The laboratory studies were supported by Deutsche Forschungsgemeinschaft GR 1096-2/2 and 2/3, and 2/4. Analysis of the HAT-3 data and the HAT-1, -2, -3 meta-analysis was supported by a grant from Berlex Laboratories (Montville, NJ) and Pharmion (Cambridge, UK). The study on a comparison of danaparoid and lepirudin was supported by Organon NV (Oss, The Netherlands) and Thiemann/Celltech (Essen, Germany). The assistance of Theresia Lietz in data analysis is highly appreciated.

0 0

Post a comment